search octane
Automated, closed-system process to support Currus’ Phase 1 trial in mesothelin-positive solid tumours, with first patient dosing expected in early 2027
October 26, 2026
Collaboration builds on CAR-T commercialization in New Zealand and supports expansion across Australia, North America and other international markets.
April 7, 2026
Kingston, Ontario, March 3, 2026 - Octane Medical Group (“Octane”) today announced that it has entered into a definitive agreement to acquire Lonza’s Personalized Medicine business.
March 3, 2026
Kingston, Ontario, January 2, 2025 – The Octane Medical Group is pleased to announce that the contract development and manufacturing arm of its German subsidiary TETEC AG is now Octane CDMO, an expanded operation with the know-how, years of experience, technology, systems and international network to drive complex, personalized cell therapies from concept to commercialization.
January 2, 2025
Kingston, Ontario, Canada / Melsungen, Germany, June 5th, 2024 – Octane Medical Group, through its new venture Octane Biotherapeutics (BioTx), has acquired 100% shares of the global orthobiologics business from its long-term partner B. Braun. The acquisition, consisting of the two companies TETEC AG in Germany and Aesculap Biologics, LLC. in the United States, establishes Octane as an international leader in regenerative medicine.
June 5, 2024
